BNGO
BIONANO GENOM (BNGO)
NASDAQ
$1.16+$0.01 (+1.22%)
Price as of Jun 23, 2026 5:27 PM EDT
  • $13.2M
    Market Cap
  • -64.83%
    1-Year Change
  • Medical Instruments & Supplies
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 70
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering

Bionano Genomics completed a public offering of 5 million shares and warrants, raising approximately $10 million gross proceeds to be used for working capital and general corporate purposes.

09/17/2025, 5:00 PM • GlobeNewswire

Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering

Bionano Genomics has priced a public offering of 5 million shares and accompanying warrants at $2.00 per share, expecting to raise approximately $10 million for working capital and general corporate purposes.

09/16/2025, 9:10 AM • Benzinga

Peers

Statistics

More
Day Range
$1.14
$1.17
$1.15
1-Year Range
$1.09
$4.92
$1.15
Latest Close$1.15
Change
+$0.01 (+0.87%)
Volume68,807
Market Cap$13.2M
Shares Outstanding11.5M
P/E (TTM)-0.27
Diluted EPS (TTM)-$4.22
Enterprise Value$39.9M

Information as of 06/22/2026

Company Profile

BIONANO GENOMICS INC
BIONANO GENOMICS INC
https://bionano.com
$13.2M
Market Cap
-$31.6M
Net Income
Sector: Healthcare
Industry: Medical Instruments & Supplies
9540 Towne Centre Drive, San Diego, CA, United States, 92121
858 888 7600

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Key Executives

  • Robert Erik Holmlin
  • Mark Oldakowski
  • Alka Chaubey FACMG
  • Albert A. Luderer
  • Cory Kreeck

Current Ownership Distribution

  • Institutions536.4M (63.97%)
  • Mutual Funds296.2M (35.33%)
  • Insiders5.9M (0.70%)
  • Other0 (0.00%)